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ABSTRACT 
Objective: The objective of this research is to clone and express a new fibrinolytic enzyme encoding serine protease gene in Escherichia coli thus, 
characterize such purified recombinant.  
Methods: The recombinant clone was successfully expressed in Lemo21 system and purified using immobilized nickel cation affinity 
chromatography on a His•bind resin®, followed by ammonium sulfate precipitation and protein filtration in combination. General properties of the 
purified enzyme were investigated, including the molecular weight, effects of inhibitors and metal ions, substrate specificity, amylolytic activity, 
fibrinolytic activity and effect of anticoagulant activity in-vitro. 
Results: The recombinant clone was expressed in Lemo21 system in the cytoplasm in a soluble and active form. The resulting enzyme, SERpro was 
purified to homogeneity with a purification of 19.35-fold and recovery yield of 4.85%. The enzyme exhibited maximal activity at 37 °C and at pH7.4, 
respectively. The molecular weight of the purified enzyme was 82 kDa, determined using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. The fibrinogenolysis peptide sequence analysis revealed that SERpro degraded Bβ chain of Fibrin at a much lower rate but cleaved 
Aα and γ-chain extensively. The enzyme was activated by metal ions such as Mg2+, Fe3+and Zn2+
Conclusion: The study deduced SERpro as a new protease with anti-thrombotic activity from Acinetobacter baumannii TU04.  
, and was inhibited strongly by PMSF. The clotting 
time of human blood serum in the presence of 1U SERpro reached a relative partial thromboplastin time of 13.9% with a 1.14-fold increase.  
Keywords: Fibrinolytic enzyme, Acinetobacter baumannii, subtilisin-like serine protease, Lemo21 expression host, Anticoagulant. 
 
INTRODUCTION 
Cardiovascular diseases (CVDs) are caused by the disorders of heart 
and blood vessels [1]. According to health data statistic published by 
World Health Organization (WHO) 2013, CVDs are projected to 
remain as the single leading cause of mortality, accounting for 23.3 
million deaths in 2030 [2-3]. Thromboembolism is the most 
prevalent type of CVD [4]. Thrombolytic therapy is the best way to 
achieve recanalization for this complication [5-8]. Thrombolytic 
agents characterized by its ability to hydrolyze thrombi via direct 
degradation or plasmin activation reveals a significant importance in 
the prevention and treatment of thrombosis [8]. Various potent 
thrombolytic agents have been successfully identified and 
characterized from animals [9-11], plants [12] and microorganism 
[7, 13-15]. 
Recently, studies have also demonstrated the efficacy of 
thrombolytic agents such as tissue-type plasminogen (t-PA) [16-17], 
single-chain urokinase-type plasminogen activator (scu-PA or 
pro-urokinase, Pro-UK) [18] and plasmin-like protein [19] in the 
recanalization and reperfusion of thrombo-embolism. However, 
their hemorrhagic side-effects, low specificity, modest reliability and 
benefits [8] have prompted a quest for alternative agents, from other 
sources that are safer and more potent to be developed into 
therapeutic drugs for thrombo-embolism.  
In general, fibrinolytic agents derived from Asian traditional 
fermented foods can function as an adjunct to conventional 
cardiovascular disease therapy through their incorporation as food 
additives and nutraceutical application, which can help in 
preventing cardiovascular disease [6, 14]. In this study, a bacterial 
strain isolated from Tapai Ubi, a traditional Malaysian fermented 
food, identified as Acinetobacter baumanii TU04 [20] were analyzed 
for its thrombolytic potential. Prior to our report, fibrinolytic 
proteases had not yet been reported from Acinetobacter baumannii, 
therefore, in this study we describe the molecular cloning and 
expression of a new fibrinolytic enzyme encoding serine protease 
gene in Escherichia coli and the characterization of the purified 
recombinant enzyme.  
MATERIALS AND METHODS 
Chemicals 
Human plasma fibrinogen, Thrombin (EC 3.4.21.5) from bovine 
(Calbiochem Cat# 605157), Plasmin from human plasma (10 602 
361 001) [5U], Plasminogen, Perfect ProteinTM
Bacterial strains and growth conditions 
 Marker (Novagen, 
69149-3) and Prestained Protein Marker, (NEB#P7702) were used. 
Specific kits for sample extraction and purification were purchased 
from Promega and Qiagen. Sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) set and reagents were bought from 
Bio-Rad Co. (Richmond, CA, USA). Chromatography column and 
His® Bind resin were purchased from GE Healthcare. Other fine 
chemicals and reagents used were of analytical grade. 
Acinetobacter baumannii TU04 isolated from Tapai Ubi, a traditional 
cassava-fermented food, was grown at 37 °C, 200rpm for 16 h in 
basal medium containing 1% (w/v) tryptone, 0.5% (w/v) beef 
extract, 1% (w/v) NaCl, pH 7.0±0.2 (Accession No: KP204010). 
Escherichia coli DH5α was used in cloning steps and Lemo21 (DE3), 
which contains the T7 RNA polymerase gene under the 
IPTG-inducible lacUV5 promoter, was used for the expression of the 
enzyme under T7 promoter control. Escherichia coli strains were 
cultured in Luria-Bertani (LB) medium supplemented with 
ampicillin of 100 µg/ml at 37 °C when necessary. 
Construction of protease cloning and expression system 
Genomic DNA of Acinetobacter Baumannii TU04 was isolated by the 
procedure as described Sambrook (1989) [21]. Two degenerate 
oligonucleotide primers were synthesized to amplify DNA fragments 
encoding the subtilisin-like serine protease gene: forward primer, 
AsLfEco R1: 5’ GCC GCA GAA TTC ATG ACA AGG ATA ATC GTA GCA 
TCC 3’ (with Eco R1 restriction site as underlined) and reverse 
primer, AsLrXho 1: 5’ CTG GCT TCT CGA GCT AAA CAA CTG GGT AAG 
TCT GAT 3’ (with Xho 1 restriction site shown as underlined). These 
primers were synthesized based on sequences of the conserved 
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regions of previously cloned fibrinolytic proteases of Bacillus, 
collected from GenBank. The PCR mixture was prepared in a total 
volume of 50 µl containing 5U FirePol DNA polymerase, 10X buffer B, 
25 mM MgCl2
The amplicons were digested with Eco R1 and Xho 1, and the 
isolated fragments ligated into Eco R1 and Xho 1 digested pET-22b 
(+) vector (Novagen, Darmstadt, Germany). The resulting plasmids 
were named as pET22SERpro and was introduced into E. coli DH5α. 
DNA manipulations including digestion with restriction enzymes, 
purification of DNA fragments, ligation with T4 DNA ligase and 
transformation were performed as described by Sambrook (1989) 
[21]. The analysis of sequence data and sequence similarity searches 
were performed using the BLASTn program of the National Center 
for Biotechnology Information (NCBI). Homology alignment was 
performed with the CLUSTALw program using MEGA Version 6.06 
software. The plasmid DNA prepared from these clones was then 
sub-cloned into the expression host, Lemo21 (DE3).  
, 20 mM dNTP mix, 10 µM forward and reverse primer 
each and approximately 3-5ng of genomic DNA of Acinetobacter 
baumannii as the template. The PCR product of about ~2.2 kb was 
gel extracted, and its nucleotide sequence was determined.  
Gene expression of SERpro 
E. coli cells strain Lemo21 (DE3) (New England Biolabs, C2528H) 
harboring the recombinant pET22b-SERpro were grown in Luria 
Bertani medium supplemented with 50 µg/ml of ampicillin, 100 
µg/ml chloramphenicol and 1000 µM L-rhamnose at 37 °C, with 
shaking until growth reached A600 nm~0.65. Expression of the gene 
was induced by addition of IPTG to a final concentration of 0.4 mM 
and the incubation was further extended for an additional 19 h at 
30 °C. The cells were harvested by centrifugation at 5,500 rpm for 
30 min at 4 °C, washed twice in 1X PBS buffer (pH8.0) containing 5 
mM MgCl2
Purification of the recombinant SERpro enzyme 
, resuspended in the same buffer with the addition of 5 
mM lysozyme and lysed by sonication for 10 min with a 5 sec pulse. 
The samples were then centrifuged at 8,100 rpm for 20 min to 
separate and remove the insoluble fractions. 
The cell-free extract from the lysate from 3L of induced cells 
harboring pET22b-SERpro was used for purification of recombinant 
protein. All purification steps were carried out at 4 °C. The extracted 
protein were adjusted to the final concentration of 50 mM 
Phosphate buffer (pH7.4) and were pre-incubated with His•bind 
resin® at 4 °C with slow agitation for at least an hour though 
generally not longer than 3 h. Following incubation, the resin 
containing bound SERpro+His protein was transferred to a gravity 
flow column® (2.6 cm X15 cm) and washed with 20 column volume 
(CV) of buffer A (50 mM Phosphate buffer; pH7.4 with 1% Triton 
X-100). The protein of interest was eluted using elution buffer 
(buffer A containing 250 mM imidazole) at a flow rate of 1.0 
ml/minute. Fractions containing the protein were pooled and 
dialyzed against buffer B (50 mM Phosphate buffer; pH7.4) and 
concentrated using VivaFlow 10, 000 MWCO, PES membrane. The 
concentrated eluates were pooled and subjected to 60% ammonium 
sulphate precipitation. The precipitated enzyme was dissolved in 
buffer B and dialyzed against buffer B to remove salt in excess, and 
analyzed for purity by SDS-PAGE. Protein concentration was 
determined according to Bio-Rad protein assay with bovine serum 
albumin (BSA) as the standard. A blank was prepared in same 
conditions, but enzyme was replaced with buffer. The assays were 
performed in triplicates. 
Enzyme activity assay  
Fibrinolytic enzyme activity was determined colorimetrically, using 
synthetic fibrin clot methods [22-23] with minor modifications. The 
reaction mixture containing 1% (v/v) fibrinogen human plasma, 
10U thrombin from bovine, 50 mM phosphate buffer (pH 7.4±0.2) 
and purified enzyme was incubated at 37 °C for 180 min. The 
reactions were stopped by the addition of 750 µl of 15% (w/v) 
trichloroacetic acid (TCA) solution (0.11M TCA, 0.22M Sodium 
acetate and 0.33M acetic acid) for 30 min at room temperature. The 
reaction mixture was centrifuged at 5,500 rpm for 10 min and 100 µl 
of supernatant was incubated with 2 ml of 0.55M Na2CO3
Amidolytic activity was assayed using Kim (1996) [7] methods with 
minor modifications. One unit of amidololytic activity (AU) was 
expressed as micromoles of substrates hydrolyzed per minute per 
milliliter by the enzyme. The kinetic constant was determined using 
Hanes-Woolf plots based on the initial reaction rates. 
 and 1 ml 
of Folin-Ciocalteau (Sigma Aldrich; St. Louis, MO, USA) at 37 C for 30 
min. The absorbance was recorded at 660 nm. Caseinolytic activity 
was assayed according to Lee, (2006) [22]. One unit of fibrinolytic or 
caseinolytic activity (CU) was defined as the amount of enzyme 
releasing 1 µmol of tyrosine equivalent per min under the assay 
conditions.  
SDS-PAGE analysis and Immunoblotting 
SDS-PAGE was performed on 12% running gel as described by 
Laemmli (1970) [24], and the resolved proteins were visualized by 
coomassie staining. For western blot analysis, protein samples were 
subjected to SDS-PAGE and then wet-transferred onto nitrocellulose 
membrane. The membrane was blocked with 3% (v/v) skim milk in 
PBST (20 mM PBS, pH 8.0, 0.1% Tween-20) at room temperature for 
at least 1 h, and then incubated with mouse anti his: hrp conjugated 
antibody in PBST with 1% (v/v) skim milk (diluted 1:1000). 
Immunodetection was performed using the Opti 4CN substrate kit 
according to manufacturer’s instructions.  
Effect of pH on fibrinolytic activity and stability 
The following buffers were used to investigate the effect of pH upon 
the purified enzyme activity: 100 mM sodium acetate buffer, pH 
4.0-5.0, 100 mM sodium phosphate buffer; pH 6.0-7.0, 100 mM 
Tris-HCL; pH 8.0-9.0 and 100 mM glycine-NaOH buffer; pH 10.0-11.4. 
The optimal pH for the purified enzyme was determined by 
incubating the enzyme at 37 °C with different buffers and the 
residual activities were determined. The effect of pH on enzyme 
stability was determined by pre-incubating the purified enzymes in 
buffers with different pH values for 24 h at 37 °C.  
Effect of temperature on fibrinolytic activity and stability  
The optimal temperature for the purified enzyme was determined 
over the range of 08-60 °C by spectrophotometric assay. The 
thermal stability was determined by incubating the purified enzyme 
at various temperatures for 60-240 min at pH 7.4, and the residual 
activity were measured.  
Effect of metal ions and protease inhibitors 
The effect of metal ions on the enzyme activity was determined 
using CoCl2, MgSO4, ZnSO4, MnCl2, Fe2 (SO4)3, KCL, CuSO4 and CaCl2. 
The effect of protease inhibitors were investigated using 5 mM of 
diamine tetraacetic acid (EDTA), phenylmethylsulfonyl fluoride 
(PMSF), 2-mercaptoethanol, ethylene glycol tetraacetic acid (EGTA) 
and Dithiothreitol (DTT). The enzyme was pre-incubated with the 
protease inhibitors at 37 °C for 30 min and the residual activity was 
determined spectrophotometrically. 
The purified enzyme was pre-incubated with various metal ions at a 
concentration of 5 mM for 6 hr at 37 °C and the residual activities 
were determined. The activity of the enzyme in the absences of 
metal ions was taken as 100%. 
Fibrinogenolytic activity analysis 
A reaction mixture consisting of 30 µl 1% (w/v) human fibrinogen 
solution in 50 mM Tris-HCl buffer, pH7.8 containing 0.1M sodium 
chloride was prepared. 30 µl of the purified enzyme was incubated 
with the reaction mixture at 37 °C for 24 h. At each interval of 3 h, 
the reaction was stopped by adding 90 µl of denaturing solution (4% 
(w/v) SDS, 4% (v/v) 2-mercaptoethanol and 10M Urea). The 
polymerizations of fibrinogen monomer were observed by turbidity 
changes with time and were separated on 12% SDS-PAGE gel 
according to Laemmli method. Fibrinogen without SERpro enzyme 
was pre-checked as a negative control.  
In vitro coagulation assays 
Anticoagulant activity in vitro was determined as an increase in the 
relative partial thromboplastin time (RPTT) using a Batomunkueva 
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and Egorov (2001) [25] modification of the method described by 
Strukova (1989) [26]. The reaction mixture containing 0.1 ml of the 
human blood serum, 0.1 ml of a thromboplastin suspension and 0.1 
ml of kaolin was incubated in a water bath at 37 °C for 2 min and 
then rapidly mixed with 0.1 ml of 0.3% (w/v) CaCl2
To obtained the clones with fibrinolytic enzyme gene of 
Acinetobacter baumannii TU04, potential serine protease encoding 
fibrinolytic enzyme gene sequence of Bacillus was aligned with the 
chosen subtilisin-like serine protease gene of Acinetobacter 
baumannii obtained from GenBank of NCBI. Sequences with high 
similarity; the subtilisin-like serine protease gene from A. baumannii 
MDR-ZJ06 deposited by Zhou (2011) [27] with the Accession No: 
YP_005526853.1 were referred as the potent fibrinolytic protease 
gene and were subjected as the study template for cloning. The 
full-length sequence of the gene of interest was intensively analyzed 
(data not shown) and cloned using pET-22b cloning/expression 
vector. The obtained recombinant clone was introduced into E. coli 
DH5α and the open reading frame (ORF) of the DNA fragment was 
analyzed.  
. The time of the 
blood serum clotting was determined using a stopwatch after 
addition of 0.1 ml of pure enzyme. The control mixture contained an 
equivalent amount of 0.86% (w/v) physiological saline solution. The 
relative PTT was calculated using the formula [(A-B)/B] X 100%, 
where A and B are the time (in seconds) of the blood serum clotting 
in the presence and absence of the enzyme, respectively. The data 
was expressed as mean values of three replications. 
RESULTS AND DISCUSSION 
Cloning and sequencing of the protease gene  
The gene sequence analysis of the plasmid pET-22b of about 
5,943bp with gene insert of 2.184kb revealed an open reading 
frame (ORF) starting at bp 360 with an ATG codon and ending at a 
TGA codon at 2214, thereby encoding a protein of 739 amino acids. 
The nucleotide sequence and the deduced amino acid sequence 
were shown in fig.1. GenBank accession number for this sequence 
is KP204011. The ORF translated protein has a predicted 




Fig. 1: The nucleotide and deduced amino acid sequences of genomic DNA encoding SERpro clone 
 
A BLASTx search of the completely deduced amino acid sequence of 
the gene (739 amino acid; Fig.1) showed a high homology of about 
98% (1370 total score) with subtilisin-like serine protease of 
Acinetobacter baumannii [Gen Bank accession number 
WP_002000057.1]. The recombinant clone do not have any signal 
peptide sequence based on its amino acid composition and 
hydrophobicity profile, a common characteristic of the extracellular 
protease. 
The deduced amino acid sequence of the gene (fig. 1) was also 
aligned with other established fibrinolytic enzymes; protein 
sequences obtained from the protein database of NCBI using 
CLUSTALw program using MEGA Version 6.06 software. The 
resulting phylogenetic tree was illustrated in fig. 2. The dendrogram 
analysis showed an analogous sequence similarity of about 89% 
with other established fibrinolytic proteases. The apparently high 
level of sequence similarity suggests that this protein could be a new 
protease with fibrinolytic function.  
Over-expression and purification of the recombinant clone 
Plasmid pET22b-SERpro was transformed into Lemo21 (DE3) 
system to express the target protein, regulated by the 
IPTG-inducible lacUV5 promoter. SDS-PAGE analysis showed that 
SERpro-His-tagged protein was successfully expressed after 
induction with 0.4 mM IPTG for 19 h at 30 °C (fig. 3, lanes 3 and 5). A 
new protein band corresponding to the expected size (~82kda) was 
observed in total cell extract and soluble fraction of induced cells. 
The amount of expressed protein, SERpro was approximately 6.8% 
of the total soluble proteins of the intracellular fraction. These 
results indicated that this protein was not efficiently over-expressed 
in the cytoplasm of Lemo21 although optimization was carried out 
in the presence of increasing concentration of L-rhamnose in 
standard Luria-Bertani broth (result not shown). 
SERpro was purified from the intracellular fraction of Lemo21 using 
a combination of chromatographic steps summarized in table 1. The 
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measured protein concentration, fibrinolytic activity and SDS-PAGE 
analysis were used as indices of purification. The recombinant 
SERpro purification steps gave an overall purification of 19.35 fold. 
The overall activity yield of the purified SERpro was 4.85% with a 
specific activity of 2.07 U/mg of protein. The purified SERpro was 
delineated to be homogeneous based on SDS-PAGE (fig. 3, lane 7). 
Western blotting revealed that the band indeed corresponded to a 
recombinant his-tagged protein (fig. 3, lane 8). The apparent 
molecular weight of the enzyme was calculated based on the bands 
separations on SDS-PAGE using a standard curve established with 
the proteins of known molecular weight. The predicted molecular 
weight of SERpro 76,028 kDa correlates with the purified SERpro 




Fig. 2: Dendrogram generated based on the protein sequence alignment of the SERpro protease gene of Acinetobacter baumannii TU04 
with references fibrinolytic enzymes using bootstrap replication of 1,000. Reference fibrinolytic protease sequences are shown with their 
respective gene bank accession number 
 
 
Fig. 3: SDS-PAGE analysis illustrating expression and purification of recombinant SERpro. Lane M: Perfect ProteinTM
 
 marker; Lanes 1 
and 2: IPTG-induced and uninduced whole cell lysate without SERpro gene insert, respectively; Lanes 3 and 4: IPTG-induced and 
uninduced whole cell lysate with recombinant SERpro gene, respectively; Lane 5: The extracted membrane protein from the 3L lysate 
of induced pET22b-SERpro transformant; Lane 6: Purified sample using His-bind resin; Lane 7: Purified SERpro after subjected to 
60% ammonium sulfate precipitation; Lane 8: Immunoblotting assay using mouse anti his: hrp conjugated antibody at the C-terminus 
of the recombinant SERpro 
Table 1: Purification summary of the SERpro enzyme from Lemo21 










Crude lysate  73.8  690.84 0.107 100 1 
His•bind resin   53.13 51.25 0.833 71.99 7.785 
Ammonium sulfate precipitation   6.77  6.528  1.037  9.17  9.692 
VivaSpin, 50kDa  3.58  1.73  2.07  4.85  19.346 
aOne unit of total activity (U/ml) was determined by measuring the liberated 1 µmoles of L-tyrosine/ml/min at 37 °C, b
 
Yield was calculated based on 
total enzyme activity (U/ml) 
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Effect of pH and temperature on fibrinolytic activity 
The purified SERpro showed optimal catalytic activity at pH7.4 (fig. 
4a) and retained more than 60% of its activity at 37 °C for up to 24 h 
in various buffers over a pH range of 6.0-9.0 (fig. 4b).  
The optimum temperature for SERpro activity was 37 °C (fig. 5a). 
The thermal stability profile showed that the SERpro retained 90% 
of its initial activity after 4 h incubation at 37 °C and possessed<5% 









Fig. 5: Effect of temperature on the fibrinolytic enzyme (a) activity and (b) stability of SERpro 
 
Effect of metal ions and protease inhibitors on fibrinolytic 
activity 
The effect of metal ions and various protease inhibitors on the 
SERpro activity is as shown in fig. 6. The SERpro residual activity 
was calculated on the basis of the activity of enzyme without any 
metal ion or inhibitor under the same reaction condition. The 
SERpro activity increased significantly in the presences of 5 mM 
Mg2+, Fe3+and Zn2+
The fibrinolytic activity and caseinolytic activity of SERpro was 
measured and the ratio of fibrinolytic to caseinolytic activity was 
calculated. The SERpro enzyme hydrolyzed both casein and fibrin at 
0.357 U/ml and 0.5584 U/ml, respectively and with substrate 
specificity (F/C) of 1.56. This result concludes that SERpro has 
relatively high specificity for fibrin as substrate.  
The amidolytic activity of SERpro was investigated using several 
synthetic substrates (table 2). The SERpro enzyme exhibited the 
highest degree of specificity for the substrate N-Succinyl 
-Ala-Ala-Pro-Phe-pNA (for subtilisin and chymotrypsin), similar 
with other established fibrinolytic enzymes such as subtilisin natto 
(27.7 kDa) [13], subtilisin DFE from Bacillus amyloliquefaciens [15], 
IMR-NK1 from Bacillus subtilis [28], and subtilisin DJ-4 from 
but was completely inactivated by the 2 mM PMSF, 
which is a well-known serine protease inhibitor. The enzyme was 
also inhibited by EDTA and EGTA with 45% of its original activity 
was lost. However, the other inhibitors such as 2-mercaptoethanol 
and DTT only cause mild inhibition, 16.9-29.9% respectively, 
indicating the importance of the serine residue of this enzyme for 
enzyme activity. The data was expressed as mean values of three 
replications with their corresponding standard deviation.  
Substrate specificity of SERpro  
Bacillus
The Michaelis-Menten constant, Km and Kcat for the hydrolysis of 
N-succinyl-Ala-Ala-Phe-pNA were calculated to be 0.55 mM and 16.8 
S
 
sp. DJ-4 [29].  
-1
 
, respectively. The Km and Kcat value for the hydrolysis of 
Pyro-Glu-Gly-Arg-pNA was not determined due to the relatively low 
level of the amidolytic activity (AU), which were non-significant for 
SERpro characterization.
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Fig. 6: Effect of metal ions and protease inhibitors on the fibrinolytic activity of SERpro enzyme 
 
Table 2: Amidolytic activity of SERpro enzyme a
Synthetic substrate 
 with different synthetic substrates 
Characteristic Concentration (mM) Amidolytic activity (AU) 
H-D-Val-Leu-Lys-pNA Plasmin b 0.5 59.17±0.71 
Pyro-Glu-Gly-Arg-pNA Urokinase 0.5 1.53±0.02 
N-Succinyl-Ala-Ala-Pro-Phe-pNA Subtilisin or Chymotrypsin  0.5 136.42±0.41 
aData are expressed as mean values of three replications with their corresponding standard deviation, b
 
pNA, p-nitroanilide 
Fibrinogenolytic activity analysis 
The fibrinogenolytic mode and rate of hydrolysis for the SERpro was 
elucidated using SDS-PAGE. As illustrated in fig. 7, the SERpro 
rapidly degraded the Aα and γ-chain but hydrolyzed Bβ chains at a 
much lower rate. The peptide (MW~37.5kDa) remained uncleaved 
even after 24 h of incubation. This remnant peptide could be γ’ 
species originated from polypeptide fragment D. This species was 
less susceptible to SERpro enzyme may be due to the fact that the 
three subunit chains of fibrinogen differed in their physical and/or 
chemical compositions [30]. As a summary, the fibrinogenolysis 
pattern of SERpro was determined to be Aα->Bβ->γ-, which was 
found to be similar with PPFE-1 [8] and subtilisin DJ-4 [29].  
 
 
Fig. 7: Fibrinogen hydrolysis by the SERpro fibrinolytic enzyme. 
Lane 1: Fibrinogen without SERpro enzyme after 24h 
incubation; referred as negative control; Lanes 2-8: 
Fibrinogenolytic products of SERpro incubated at 37°C; reaction 
stopped at every 3hr interval for 24h 
 
Clotting time 
The coagulation mechanisms of the SERpro was analyzed by the 
relative partial thromboplastin time (RPTT), which is a common 
clinical test for measuring the efficacy of the both extrinsic and the 
common coagulation pathways [1, 25]. The anticoagulant activity of 
SERpro enzyme was expressed as relative PTT (%) (table 3). Based 
on the table 3 results, the clotting time of human blood serum was 
substantially prolonged with SERpro fibrinolytic enzyme to 94 s in 
the presences of 1.0U of the purified SERpro; thus relative PTT 
reached 13.9% with the 1.41-fold increase. Similar value has been 
reported by Wesam (2011) [31] for fibrinolytic enzyme K42 from 
Bacillus subtilis K42. However, a higher dosage of about 100U/0.1 ml 
enzyme was used to analyze the anti-thrombotic effect, resulting 
RPTT of 241.7%. Correlatively, if a higher dose of SERpro enzyme 
were envisaged, it is presumed that SERpro would be the 
pre-eminent. This feature resolute SERpro as a potent anticoagulant 
and/or thrombolytic agent. 
 
Table 3: In vitro application of SERpro fibrinolytic enzyme as 
anticoagulant 
Dose (U/0.1 ml) Clotting time (s) RPTT 
(%) 
Controls 82.5±0.71 0.0 
0.5 87±0.5 5.5 
1.0 94±0.83 13.9 
 
CONCLUSION 
The overall findings of SERpro with respect to the molecular weight, 
effects of inhibitors and metal ions, substrate specificity, 
fibrinogenolytic activity and effect of anticoagulant indicate SERpro 
as a new fibrinolytic enzyme. In conclusion, the present results 
suggest SERpro fibrinolytic enzyme obtained from Acinetobacter 
baumannii TU04 may become a new source of fibrinolytic agents 
and further studies on its safety and functional evaluations are 
required and underway. 
ABBREVIATION  
BSA, bovine serum albumin; CBB, Coomassie brilliant blue; IPTG, 
isopropyl-β-D-1-thiogalactopyranoside; pNA, p-nitroanilide, PMSF, 
phenyl methane sulfonyl fluoride; EDTA, ethylene diamine tetra 
acetate; MW, molecular weight; SDS-PAGE, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. 
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